Organ-Preserving Approach in Treatment of Uterine Leiomyoma by Moslem, Abdulrahman Abdulbaset et al.
Galician	Medical	Journal,	Vol.	23,	No.	1(2016)	
	
journal	homepage:	http://ojs.ifnmu.edu.ua/index.php/gmj/ 
88	
	
	
Abdulrahman	Abdulbaset	Moslem,	O.M.	Makarchuk,	S.O.	Kantymyr,	M.I.	Rymarchuk,	
L.M.	Vakaluk	
	
Organ-Preserving	Approach	in	Treatment	of	
Uterine	Leiomyoma	
	
Ivano-Frankivsk	National	Medical	University,	Ivano-Frankivsk,	Ukraine	
	
Keywords:	
leiomyoma;	
symptoms;	
conservative	
treatment;	
organ-
preserving	
surgeries	
	
Abstract.	
	
Uterine	 leiomyoma	 is	 one	 of	 the	 most	 common	 benign	 hyperproliferative	
diseases	 of	 the	 female	 reproductive	 organs.	 According	 to	 the	 literature,	 its	 prevalence	
among	women	of	reproductive	age	is	estimated	to	be	approximately	20–40%.	Moreover,	it	
is	diagnosed	more	often	(up	to	75-85%)	when	carrying	out	morphological	investigations	of	
macro	 specimens	after	hysterectomy.	 In	 recent	years	 the	proportion	of	young	patients	
with	this	pathology	has	increased.	For	a	long	period	of	time	radical	hysterectomy	has	been	
the	 most	 common	 method	 used	 to	 treat	 the	 disease.	 During	 the	 past	 decades	 the	
possibilities	 of	 organ-preserving	 treatment	 of	 the	 disease	 expanded	 due	 to	 the	
achievements	 of	 modern	 pharmaceutical	 industry	 and	 implementation	 of	 new	
technologies.	As	a	result,	surgical	 interventions	themselves	changed	and	the	proportion	
of	 surgeries	 such	 as	 conservative	 myomectomy,	 uterine	 artery	 embolization,	
hysteroscopic	 resection	 of	 submucous	 fibroid	 increased.	 The	 data	 on	 surgical	
interventions	 allowed	 us	 to	 eradicate	 the	 symptoms	 of	 uterine	 leiomyoma	 preserving	
fertility	 in	 many	 patients,	 however,	 the	 risk	 of	 tumor	 recurrence	 and	 growth	 is	 still	
present.	 The	 recurrence	 rate	 after	 organ-preserving	 surgeries	 remains	 high	 and,	
according	to	the	results	of	various	studies,	accounts	 for	2-50%	of	cases.	Considering	the	
above-mentioned	data	prevention	of	tumor	recurrence	is	of	great	relevance.	Based	on	the	
results	 of	 diagnostic	 program	 including	 endocrinologic,	 immunological	 and	
morphological	 investigations	 there	 was	 found	 that	 in	 women	 with	 isolated	 uterine	
leiomyoma	dyshormonal	disease,	inflammatory	processes	of	the	genital	organs,	chronic	
endometritis,	 pathology	 of	 the	 receptor	 apparatus	 of	 uterine	 tissues	 occur	 more	 often;	
hyperprolactinemia,	relative	or	absolute	hyperestrogenemia	and	increased	production	of	
antibodies	are	more	often	diagnosed	in	women	with	uterine	leiomyoma	and	co-existent	
dyshormonal	pathology	of	the	mammary	and	thyroid	gland.	According	to	the	 literature,	
in	 isolated	uterine	 leiomyoma	 therapy	aimed	at	 correcting	 local	 factors	 including	anti-
inflammatory	 therapy,	 local	 hormone	 therapy	 or	 uterine	 artery	 embolization	 is	
recommended.	 In	comorbidity	correction	of	systemic	metabolic	disorders,	namely	anti-
stress	therapy,	systemic	hormone	therapy,	 immune	system	correction,	treatment	of	co-
existent	 somatic	 pathology	 which	 may	 include	 local	 use	 of	 hormones	 and	 organ-
preserving	surgical	interventions	should	be	performed	first	of	all.	Thus,	modern	medicine	
has	 in	 its	 arsenal	 various	 organ-preserving,	 conservative,	 surgical	 including	 minimally	
invasive	methods	of	treatment	implementation	of	which	allows	us	to	improve	quality	of	
life	in	such	patients	as	well	as	to	enhance	fertility	and	reproductive	health	of	women.	
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Problem	statement	and	analysis	of	the	recent	research	
Uterine	 leiomyoma	 is	one	of	 the	most	common	benign	hyperproliferative	diseases	of	 the	
female	 reproductive	 organs.	 According	 to	 the	 literature,	 its	 prevalence	 among	 women	 of	
reproductive	age	is	estimated	to	be	approximately	20–40%.	Moreover,	it	is	diagnosed	more	often	(up	
to	75-85%)	when	carrying	out	morphological	investigations	of	macro	specimens	after	hysterectomy	
[1,	4,	5].	Uterine	leiomyoma	is	the	most	common	benign	tumor	of	the	female	genital	tract	leading	
to	 infertility	 in	20-45%	of	cases	and	surgery	 including	the	removal	of	an	organ	 in	50-70%	of	cases	
and,	accordingly,	it	is	the	main	cause	of	a	performance	decrement	among	modern	women	and	the	
deterioration	in	the	quality	of	life.	Symptoms	of	leiomyoma	such	as	uterine	hemorrhage,	anemia,	
pain,	symptoms	of	compression	of	adjacent	organs	result	in	significantly	reduced	physical	health	
of	a	woman	and	deterioration	of	her	emotional	state	as	well	as	often	lead	to	female	infertility	and	
pathological	 course	 of	 pregnancy	 [2].	 In	 recent	 decades	 the	 ratio	 of	 symptomatic	 course	 of	
leiomyoma	has	increased	according	to	different	authors	from	60%	by	75%	[1-5].	In	recent	years	the	
proportion	of	young	patients	with	this	pathology	has	 increased.	According	to	Tatarchuk	TF,	et	al.	
during	a	10	years’	follow-up	of	women	being	treated	in	clinical	hospitals	of	Kyiv	the	proportion	of	
patients	at	 the	age	of	31-40	years	 increased	 significantly	while	 the	proportion	of	young	patients	
under	30	years	of	age	increased	by	almost	4	times	[9-11].	
The	objective	of	the	research	was	to	analyze	the	available	 literature	on	the	assessment	of	
this	problem	as	well	as	to	search	for	new	approaches	to	its	solution.	The	progress	of	fundamental	
sciences	 achieved	 over	 the	 past	 decades	 allowed	 us	 to	 advance	 in	 studying	 the	 etiology	 and	
pathogenesis	 of	 uterine	 fibroid.	 However,	 the	 leading	 mechanisms	 of	 its	 development	 remain	
uncertain	and	debatable.	Leiomyoma	often	develops	together	with	dyshormonal	pathology	of	the	
mammary	and	thyroid	gland,	obesity	and	hepatobiliary	disorders	[1,	9,	11,	12].	In	co-occurrence	of	
the	pathology	of	 the	mammary	gland	uterine	 leiomyoma	usually	develops	 secondary	 to	chronic	
stress	in	patients	with	a	hereditary	predisposition	to	proliferative	diseases	and	positive	anamnesis	
for	 recent	 allergic	 events.	 It	 is	 accompanied	 by	 thyroid	 dysfunction,	 high	 body	 mass	 index,	
pathology	of	the	liver	and	cardiovascular	system	while	isolated	leiomyoma	is	more	often	observed	
secondary	to	chronic	inflammatory	genital	diseases	and	vaginal	dysbiosis,	miscarriage,	prolonged	
use	of	intrauterine	contraceptive	devices	as	well	as	postabortal	and	postpartum	complications	[1,	
11,	14].	 It	should	also	be	noted	that	 isolated	 leiomyoma	 is	characterized	by	a	slow	asymptomatic	
growth	sometimes	reaching	a	large	size	and	symptoms	of	compression	of	adjacent	organs	while	in	
comorbidity	 it	 is	 often	 accompanied	 by	 rapid	 growth	 and	 pronounced	 clinical	 manifestations	
including	menometrorrhagia	and	pain	syndrome	deteriorating	the	quality	of	life	in	a	woman	even	
if	its	size	is	small	[5,	14,	15].	
Based	on	 the	 results	of	diagnostic	program	 including	endocrinologic,	 immunological	and	
morphological	 investigations	 there	 was	 found	 that	 in	 women	 with	 isolated	 uterine	 leiomyoma	
dyshormonal	 disease,	 inflammatory	 processes	 of	 the	 genital	 organs,	 chronic	 endometritis,	
pathology	 of	 the	 receptor	 apparatus	 of	 uterine	 tissues	 occur	 more	 often;	 hyperprolactinemia,	
relative	 or	 absolute	 hyperestrogenemia	 and	 increased	 production	 of	 antibodies	 are	 more	 often	
diagnosed	 in	 women	 with	 uterine	 leiomyoma	 and	 co-existent	 dyshormonal	 pathology	 of	 the	
mammary	and	 thyroid	gland.	According	 to	 the	 literature,	 in	 isolated	uterine	 leiomyoma	 therapy	
aimed	at	correcting	 local	 factors	 including	anti-inflammatory	 therapy,	 local	hormone	 therapy	or	
uterine	 artery	 embolization	 is	 recommended.	 In	 comorbidity	 correction	 of	 systemic	 metabolic	
disorders,	 namely	 anti-stress	 therapy,	 systemic	 hormone	 therapy,	 immune	 system	 correction,	
treatment	of	co-existent	somatic	pathology	which	may	include	local	use	of	hormones	and	organ-
preserving	surgical	interventions	should	be	performed	first	of	all	[1-4,	5,	12].	
However,	 despite	 the	 considerable	 progress	 in	 the	 study	 of	 the	 morphology	 and	
pathogenesis	 of	 uterine	 leiomyoma	 as	 well	 as	 the	 achievements	 of	 modern	 pharmaceutical	
industry	 and	 the	 development	 of	 new	 technologies	 it	 should	 be	 noted	 that	 surgical	 method	 of	
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treatment	of	this	pathology	 (hysterectomy	and	myomectomy)	remains	the	 leading	one.	Surgeries	
for	the	removal	of	uterine	 leiomyoma	account	 for	80%	of	planned	surgical	 interventions	while	 in	
90%	 of	 cases	 hysterectomy	 is	 performed	 in	 women	 of	 reproductive	 age	 [4,	 15].	 However,	 this	
surgical	intervention	results	in	irreversible	infertility	[4,	15].	At	the	same	time,	the	increase	in	the	
proportion	of	young	women	with	this	gynaecological	disorder	and	their	desire	to	preserve	vaginal	
function	and	the	uterus	are	quite	significant	and	according	to	various	authors	constitute	42%-65%	
[5].	 The	 analysis	 of	 the	 structure	 of	 motivation	 to	 preserve	 the	 uterus	 made	 and	 published	 by	
several	authors	allowed	us	to	detect	the	increase	in	the	proportion	of	older	women	that	is	obviously	
due	to	social	activity	of	a	modern	woman,	her	conscious	postponement	of	fertility	to	a	more	mature	
age.	On	 the	 other	hand,	 the	 introduction	 of	modern	 reproductive	 technologies	 expands	 the	 age	
limits	of	 fertility	 in	a	woman	and	creates	 the	possibilities	of	carrying	a	pregnancy	and	delivering	
babies	even	during	perimenopause	[11,	12,	14].	
The	 data	 mentioned	 above	 justify	 the	 need	 for	 wider	 introduction	 of	 organ-preserving	
methods	in	treatment	of	uterine	leiomyoma	as	well	as	the	search	for	individual	approaches	to	the	
management	of	this	category	of	patients.	The	selection	of	methods	of	treating	uterine	leiomyoma	
is	 known	 to	 depend	 on	 the	 size	 of	 the	 tumor,	 clinical	 symptoms	 and	 localization	 of	 the	 lymph	
nodes,	 age	 of	 the	 patient,	 her	 reproductive	 plans	 and	 to	 a	 greater	 extent,	 somatic	 pathology	
associated	with	 tumor	 formation.	There	 is	no	doubt	 that	 the	main	purpose	of	organ-preserving	
conservative	treatment	of	uterine	leiomyoma	is	not	only	to	eradicate	its	symptoms	and	to	restore	
reproductive	 function,	 but	 also	 to	 achieve	 stable	 hemostasis	 and	 to	 prevent	 uterine	 and	
endometrial	cancer.	 In	pathogenetic	treatment	of	uterine	 leiomyoma	non-hormonal	medications	
and	 hormone	 therapy	 aiming	 at	 inhibiting	 growth	 of	 tumor	 cells	 as	 well	 as	 at	 preventing	 the	
development	 of	 complications	 are	 used.	 Considering	 the	 results	 of	 fundamental	 studies	 and	
mechanisms	 of	 developing	 leiomyoma	 there	 were	 introduced	 anti-stress	 therapy	 and	 immune-
modulating	 therapy	 as	 well	 as	 anti-inflammatory,	 antioxidant,	 angioprotecive,	 antiplatelet	
therapies,	vitamins,	lymphatic	drugs	[1,	3,	5,	12].	
Hormone	therapy	is	one	of	the	most	common	approaches	to	treatment	of	hyperproliferation	
of	 the	 uterus	 and	 its	 use	 is	 based	 on	 the	 concept	 of	 hormone-dependence	 of	 cancer	 creating	
absolute	or	relative	hypoestrogenemia.	However,	the	use	of	progestogens	and	oral	contraceptives	
is	mainly	aimed	at	eradicating	symptoms	of	menometrorrhagia;	it	does	not	significantly	affect	the	
size	of	myomatous	nodules	and	 results	 in	a	 range	of	side	effects.	Prolonged	use	of	progestogens	
requires	careful	monitoring	of	hemostasis	and	lipid	profile	[13,	14,	17].	
High	 rates	 of	 co-occurrence	 of	 uterine	 leiomyoma	 and	 somatic	 pathology	 (hypertensive	
disease,	 diabetes	 mellitus,	 obesity,	 hepatobiliary	 disorders)	 require	 the	 prevention	 of	 systemic	
effects	 of	 gestagens	 by	 means	 of	 their	 local	 application	 using	 the	 levonorgestrel-releasing	
intrauterine	 system.	 The	 use	 of	 the	 levonorgestrel-releasing	 intrauterine	 system	 is	 effective	 in	
eradicating	clinical	symptoms	of	 leiomyoma	and	preventing	co-existent	endometrial	hyperplasia	
being	 not	 associated	 with	 systemic	 side	 effects	 (headache,	 mastalgia,	 acne).	 However,	 its	
application	does	not	provide	any	evidence	of	decreased	size	of	fibromatous	nodules	and	the	uterus	
in	general	and	has	several	contraindications	 (submucous	node,	endometrial	polyposis)	 [2].	Based	
on	 the	 hypothesis	 suggesting	 that	 leiomyomas	 are	 progesterone-dependent	 tumors	 and,	
accordingly,	 they	 increase	 in	 size	 when	 using	 progestogens,	 as	 presented	 in	 the	 literature,	
significant	 reduction	 in	 uterine	 size	 by	 26.5%	 was	 observed	 when	 using	 antiprogesterone	 drugs	
(mifepristone)	for	3	months	[2].	
Based	 on	 the	 currently	 existing	 literature	 data	 on	 stimulating	 effect	 of	 estrogens	 and	
progesterone	 on	 myomatous	 nodules	 the	 most	 pathogenetically	 justified	 method	 of	 hormone	
treatment	of	leiomyoma	includes,	without	a	doubt,	drugs	inhibiting	the	synthesis	of	sex	steroids.	
Nowadays	one	of	 the	most	 common	methods	 to	 reduce	 the	 synthesis	of	ovarian	 sex	 steroids	 is	
medically	induced	menopause	by	means	of	gonadotropin-releasing	hormone	(GnRH)	analogs.	This	
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group	 of	 drugs	 inhibits	 the	 synthesis	 of	 estrogens	 and	 progesterone	 blocking	 the	 production	 of	
gonadotropic	hormones	of	 the	pituitary	 gland	under	 conditions	of	 controlled	hypohormonemia.	
Estrogen	and	progesterone	deficiencies	lead	to	the	reduction	in	uterine	blood	flow,	tumor	size	and	
symptom	 severity.	 In	 addition,	 GnRHs	 inhibit	 the	 activity	 of	 certain	 growth	 factors	 (insulin-like	
growth	factor	1,	epidermal	growth	factor	in	particular)	and	cell	proliferation	as	well	as	reduce	the	
sensitivity	 of	 tumor	 to	 estrogens.	 This	 group	 of	 drugs	 is	 also	 highly	 effective	 in	 eradicating	
symptoms	of	fibroid	in	terms	of	stopping	bleeding,	reducing	symptoms	and	signs	of	pain	syndrome	
as	 well	 as	 reducing	 the	 size	 of	 nodules.	 However,	 the	 use	 of	 these	 preparations	 is	 limited	 by	 a	
significant	 number	 of	 estrogen	 deficient	 conditions	 including	 vegetative-vascular	 and	
psychopathological	manifestations	 and	 in	prolonged	use	 –	by	metabolic	disorders	of	bone	tissue	
trophism.	Considering	all	the	above-mentioned	data	this	group	of	drugs	may	be	recommended	to	
use	 as	 an	 independent	 method	 in	 conservative	 therapy	 for	 leiomyoma	 among	 female	 patients	
during	perimenopause	as	well	as	a	complex	or	combined	preoperative	preparation	[1,	5,	7,	8].	
In	 recent	 years,	 some	 cases	 regarding	 the	 use	 of	 antigonadotropins	 which	 inhibite	 the	
secretion	of	FSH	and	LH	blocking	ovarian	steroidogenesis	(danazol	and	synthetic	steroidal	hormone	
–	gestrinone)	with	the	aim	of	creation	of	hypoendocrine	profile	have	been	reported	in	the	literature.	
However,	wide	introduction	of	these	drugs	is	limited	by	their	androgenic	effects.	
Thus,	the	possibilities	of	organ-preserving	treatment	of	the	disease	expanded	significantly	
due	 to	 the	 achievements	 of	 modern	 pharmaceutical	 industry	 and	 implementation	 of	 new	
technologies.	 As	 a	 result,	 surgical	 interventions	 themselves	 changed	 and	 the	 proportion	 of	
surgeries	such	as	conservative	myomectomy,	uterine	artery	embolization,	hysteroscopic	resection	
of	 submucous	 fibroid	 increased.	 With	 the	 development	 of	 laparoscopic	 surgery	 laparoscopic	
technique	 for	 the	myolysis	of	uterine	 fibroids	 (myoma	 coagulation)	was	developed	 in	Germany.	
Laparoscopic	myolysis	and	laser	photocoagulation	under	ultrasound	guidance	is	used	primarily	to	
treat	 small	 nodules	 [15].	 New	 possibilities	 of	 organ-preserving	 therapy	 appeared	 due	 to	 the	
introduction	 of	 minimally	 invasive	 techniques	 in	 practice.	 Among	 them	 bilateral	 endovascular	
uterine	 artery	 embolization	 is	 one	 of	 the	 most	 promising	 methods	 [16].	 The	 data	 on	 surgical	
interventions	allowed	us	 to	eradicate	 the	symptoms	of	uterine	 leiomyoma	preserving	 fertility	 in	
many	patients,	however,	the	risk	of	tumor	recurrence	and	growth	 is	still	present.	The	recurrence	
rate	after	organ-preserving	surgeries	remains	high	and,	according	to	the	results	of	various	studies,	
accounts	 for	 2-50%	 of	 cases	 [5].	 In	 addition,	 though	 the	 methods	 of	 organ-preserving	 surgery	
improved	they	are	still	surgical	interventions	with	some	disadvantages	and	complications.		
	
Conclusions	
Thus,	modern	medicine	has	 in	 its	arsenal	various	organ-preserving,	conservative,	surgical	
including	minimally	invasive	methods	of	treatment	implementation	of	which	allows	us	to	improve	
quality	of	 life	 in	such	patients	as	well	as	 to	enhance	 fertility	and	 reproductive	health	of	women.	
The	optimization	of	the	algorithms	for	organ-preserving	treatment	of	uterine	leiomyoma	opens	up	
new	horizons	in	terms	of	the	preservation	of	reproductive	potential	being	of	great	medical,	social	
and	economic	 importance.	Considering	a	high	prevalence,	diametrically	opposed	 interpretations	
of	 the	 mechanism	 of	 tumor	 development,	 the	 absence	 of	 unified	 approaches	 to	 diagnosis	 and	
differentiated	 organ-preserving	 treatment	 of	 leiomyoma	 further	 study	 of	 the	 etiology	 and	
pathogenesis	as	well	as	the	development	of	the	system	of	providing	medical	and	preventive	care	
for	women	with	this	pathology	are	promising.		
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